《公司業績》香港科技探索(01137.HK)半年純利1.28億元升33.4% 中期息維持8仙
香港科技探索(01137.HK)公布截至今年6月底止中期業績,營業額19.22億元,按年升26.6%。純利1.28億元,按年升33.4%;每股盈利0.14元。派中期息8仙,按年持平。
期內集團經調整EBITDA為1.96億元,按年升35.5%。整體毛利率及混合佣金率為23.5%,去年同期為24.5%。
上半年,訂單總商品交易額為41.86億元,按年增37.7%。平均每日訂單量增加至今年六月的每日4.64萬張訂單,去年同期為每日3.65萬張訂單,並於今年二月錄得新高,平均每日訂單量達5.93萬張。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.